(0.30%) 5 115.07 points
(0.24%) 38 330 points
(0.33%) 15 980 points
(-0.94%) $83.06
(5.51%) $2.03
(0.27%) $2 353.50
(0.62%) $27.71
(3.92%) $958.25
(-0.23%) $0.933
(-0.34%) $10.99
(-0.57%) $0.796
(1.67%) $93.41
@ $9.09
发出时间: 6 Apr 2024 @ 04:00
回报率: -26.88%
上一信号: Apr 5 - 02:18
上一信号:
回报率: -0.66 %
Live Chart Being Loaded With Signals
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatitis...
Stats | |
---|---|
今日成交量 | 2.06M |
平均成交量 | 4.65M |
市值 | 471.21M |
EPS | $0 ( 2024-03-27 ) |
下一个收益日期 | ( $-0.360 ) 2024-05-09 |
Last Dividend | $873.01 ( 2017-01-20 ) |
Next Dividend | $0 ( N/A ) |
P/E | -4.00 |
ATR14 | $0.0140 (0.21%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-02-02 | Roberts M Scot | Buy | 7 775 | Common Stock, par value $0.0001 |
2024-02-02 | Roberts M Scot | Sell | 2 330 | Common Stock, par value $0.0001 |
2024-02-01 | Roberts M Scot | Buy | 6 166 | Common Stock, par value $0.0001 |
2024-02-01 | Roberts M Scot | Sell | 1 801 | Common Stock, par value $0.0001 |
2024-02-02 | Roberts M Scot | Sell | 7 775 | Restricted Stock Units |
INSIDER POWER |
---|
81.81 |
Last 99 transactions |
Buy: 2 849 671 | Sell: 279 919 |
音量 相关性
Altimmune Inc 相关性 - 货币/商品
Altimmune Inc 财务报表
Annual | 2023 |
营收: | $426 000 |
毛利润: | $-51 000.00 (-11.97 %) |
EPS: | $-1.660 |
FY | 2023 |
营收: | $426 000 |
毛利润: | $-51 000.00 (-11.97 %) |
EPS: | $-1.660 |
FY | 2022 |
营收: | $-68 000.00 |
毛利润: | $-136 000 (200.00 %) |
EPS: | $-1.810 |
FY | 2021 |
营收: | $4 410.00 |
毛利润: | $0.00 (0.00 %) |
EPS: | $-0.00379 |
Financial Reports:
No articles found.
Altimmune Inc Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
First Dividend | $873.01 | 2017-01-20 |
Last Dividend | $873.01 | 2017-01-20 |
Next Dividend | $0 | N/A |
Payout Date | 2017-02-03 | |
Next Payout Date | N/A | |
# dividends | 1 | -- |
Total Paid Out | $873.01 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 0.01 | -- |
Div. Sustainability Score | 0 | |
Div.Growth Potential Score | 0 | |
Div. Directional Score | 0 | -- |
Year | Amount | Yield |
---|---|---|
2017 | $873.01 | 655.00% |
2018 | $0 | 0.00% |
2019 | $0 | 0.00% |
2020 | $0 | 0.00% |
2021 | $0 | 0.00% |
2022 | $0 | 0.00% |
2023 | $0 | 0.00% |
2024 | $0 | 0.00% |
The company does not currently pay dividends. Given its current dividend status and a low Dividend Growth Potential Score (DGPS), there's minimal likelihood of dividends being initiated soon. Considering all factors, the near-term dividend outlook for the company remains unpromising.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
OXLC | Dividend Royal | 2023-12-14 | Monthly | 14 | 10.00% | 8.50 |
OXSQ | Dividend Diamond | 2023-12-14 | Monthly | 21 | 9.10% | 8.50 |
PSEC | Dividend Royal | 2023-12-26 | Monthly | 21 | 7.04% | 8.50 |
SLVO | Dividend Royal | 2023-11-20 | Monthly | 12 | 10.77% | 8.50 |
QYLD | Dividend Royal | 2023-11-20 | Monthly | 11 | 7.50% | 8.50 |
GAIN | Dividend Royal | 2023-12-04 | Monthly | 20 | 8.19% | 8.50 |
GLDI | Dividend Royal | 2023-11-20 | Monthly | 12 | 7.15% | 8.50 |
HRZN | Dividend King | 2023-12-18 | Monthly | 15 | 6.60% | 8.45 |
USOI | Dividend Royal | 2023-11-20 | Monthly | 8 | 16.70% | 8.28 |
PFLT | Dividend King | 2023-11-15 | Monthly | 14 | 6.50% | 8.27 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | -203.67 | 1.500 | -10.00 | -10.00 | [0 - 0.5] |
returnOnAssetsTTM | -0.412 | 1.200 | -10.00 | -10.00 | [0 - 0.3] |
returnOnEquityTTM | -0.510 | 1.500 | -6.78 | -10.00 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 17.25 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 16.69 | 0.800 | 10.00 | 8.00 | [0.8 - 2.5] |
cashRatioTTM | 11.13 | 1.500 | 10.00 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.00319 | -1.500 | 9.95 | -10.00 | [0 - 0.6] |
interestCoverageTTM | 3 630.87 | 1.000 | 10.00 | 10.00 | [3 - 30] |
operatingCashFlowPerShareTTM | -1.297 | 2.00 | -0.432 | -0.865 | [0 - 30] |
freeCashFlowPerShareTTM | -1.298 | 2.00 | -0.649 | -1.298 | [0 - 20] |
debtEquityRatioTTM | 0.00346 | -1.500 | 9.99 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | -76.88 | 1.000 | -10.00 | -10.00 | [0.2 - 0.8] |
operatingProfitMarginTTM | -196.03 | 1.000 | -10.00 | -10.00 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | -112.98 | 1.000 | -10.00 | -10.00 | [0.2 - 2] |
assetTurnoverTTM | 0.00202 | 0.800 | -3.32 | -2.66 | [0.5 - 2] |
Total Score | -0.982 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | -4.89 | 1.000 | -0.595 | 0 | [1 - 100] |
returnOnEquityTTM | -0.510 | 2.50 | -4.36 | -10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | -1.298 | 2.00 | -0.433 | -1.298 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | -1.297 | 2.00 | -0.432 | -0.865 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | -0.0709 | 1.500 | -3.81 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | -177.96 | 1.000 | -10.00 | 0 | [0.1 - 0.5] |
Total Score | -2.80 |
Altimmune Inc
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。